Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Lumos Pharma Q2 2024 GAAP EPS $(0.93) Beats $(1.24) Estimate, Sales $488.000K Beat $333.333K Estimate

Author: Benzinga Newsdesk | August 01, 2024 04:40pm
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(0.93) per share which beat the analyst consensus estimate of $(1.24) by 25 percent. This is a 14.68 percent increase over losses of $(1.09) per share from the same period last year. The company reported quarterly sales of $488.000 thousand which beat the analyst consensus estimate of $333.333 thousand by 46.40 percent. This is a 7.40 percent decrease over sales of $527.000 thousand the same period last year.

Posted In: LUMO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist